Vapendavir: Phase II data

A double-blind, U.S. Phase II trial in 300 asthmatic adults with symptomatic, naturally acquired HRV infection showed that twice-daily 400 mg oral vapendavir for 6 days met the primary endpoint of reducing the severity of cold symptoms over days 2-4 after the onset of illness, the anticipated peak of infection, as measured by the mean daily difference in WURSS-21 scores vs. placebo (p=0.028). Vapendavir also significantly improved the endpoint over days 2-14 after the onset of illness vs. placebo (p=0.001). Additionally, Biota said patients treated with vapendavir improved significantly earlier, with peak symptoms occurring at 1.7 days after the onset of illness vs. 2.5 days for placebo (p=0.036). ...